New possibilities of drug-based therapy in patients with corneoconjunctival xerosis

Brzhesky V.V.¹, Kalinina I.V.², Popov V.Yu.<sup>1

1</sup> Saint Petersburg State Medical Pediatric University, Russia
² Mariinsky Hospital, St. Petersburg, Russia

Today drug-based therapy is the most convenient treatment in patients with dry eye syndrome (DES). It makes up tear deficiency in the conjunctival cavity, decreases inflammation, hyperosmolarity of the tear film and normalizes the local immunity.
The artificial tears can solve some of these problems. Metabolic therapy is effective in patients with DES. Eye drops Stillavit® contains 0.05% - sodium chondroitin sulfate, 0.16% - sodium hyaluronate and 1% - dexpanthenol, which provides comprehensive pharmacological effect, e.g. moisturizing (due to acid hyaluronic and chondroitin sulfate), stimulation of reparative processes in ocular surface tissue (due to all 3 components), and anti-inflammatory activity (due to chondroitin sulfate).
The paper addresses main directions of drug-based therapy in patients with DES (anti-inflammatory, immunomodulating, metabolic therapy and osmoprotection of ocular surface epithelium).
Keywords: dry eye syndrome, xerosis of the ocular surface, artificial tears, Stillavit.
For citation: Brzhesky V.V., Kalinina I.V., Popov V.Yu. New possibilities of drug-based therapy in patients with corneoconjunctival xerosis // RMJ. Clinical ophthalmology. 2016. № 1. P. 39–46.